Latest On CollPlant Biotechnologies Ltd (CLGN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 12:54 EST | News | CollPlant Biotechnologies Non-GAAP EPS of -$0.29, revenue of $0.43M | N/A |  |
| 2023-05-24 12:54 EST | News | CollPlant Biotechnologies Ltd. (CLGN) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-03-30 00:02 EST | News | CollPlant Biotechnologies Ltd. (CLGN) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-29 08:29 EST | News | CollPlant GAAP EPS of -$1.53 beats by $0.03, revenue of $0.3M in-line | N/A | |
| 2023-02-12 13:21 EST | News | CollPlant: Expanding End-Market Opportunities | N/A | |
| 2022-12-02 00:33 EST | News | CollPlant Non-GAAP EPS of -$0.34, revenue of $0.11M | N/A | |
| 2022-08-25 08:00 EST | News | CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M | N/A | |
| 2022-05-26 23:57 EST | News | CollPlant Non-GAAP EPS of -$0.36, revenue of $0.6M | N/A | |
| 2022-03-25 11:59 EST | News | CollPlant Non-GAAP EPS of $0.16, revenue of $15.64M | N/A | |
| 2021-12-28 02:26 EST | News | CollPlant BioTechnologies shares rally, close up 35% | N/A | |
| 2021-11-18 09:02 EST | News | CollPlant EPS beats by $0.01, misses on revenue | N/A | |
| 2021-09-22 19:45 EST | News | Collplant Biotechnologies (CLGN) Investor Presentation - Slideshow | N/A | |
| 2021-08-19 21:50 EST | News | CollPlant reports Q2 results | N/A | |
| 2021-08-13 07:54 EST | News | SA PRO Editors: CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company | N/A | |
| 2021-08-05 20:55 EST | News | CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company | N/A | |
| 2021-07-22 18:03 EST | News | CollPlant EPS beats by $0.08, misses on revenue | N/A | |
| 2021-07-22 18:03 EST | News | CollPlant announces effectiveness of uplisting to Nasdaq Global Market | N/A | |
| 2021-07-22 18:02 EST | News | 3D Systems, CollPlant sign co-development agreement 3D bioprinted soft tissue | N/A | |
| 2021-07-22 18:02 EST | News | Idera Pharmaceuticals, Beyond Air leads healthcare gainers; Mereo BioPharma, Portage Biotech among major losers | N/A | |
| 2021-03-26 22:29 EST | News | CollPlant EPS misses by $0.14, misses on revenue | N/A | |
| 2021-03-03 10:33 EST | Analyst Rating | The Analyst Target Price has decreased from $23.5 to $23. | Neutral | |
| 2021-02-25 18:26 EST | News | CollPlant gets licensing agreement termination notice from Lung Biotechnology | N/A | |
| 2021-02-12 13:33 EST | News | CollPlant Biotechnologies secures $35M capital raise | N/A | |
| 2021-02-10 10:16 EST | Analyst Rating | The Analyst Target Price has increased from $14 to $23.5. | Buy | |
| 2020-12-09 07:40 EST | Analyst Rating | The Analyst Target Price has decreased from $16 to $14. | Neutral | |
| 2020-12-07 23:29 EST | Analyst Rating | The Analyst Target Price has increased from $14 to $16. | Buy | |
| 2020-12-04 06:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-03 06:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-02 14:36 EST | News | CollPlant EPS misses by $1.79, misses on revenue | N/A | |
| 2020-12-02 07:19 EST | Earnings Estimate | An EPS average of -$0.24 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-27 01:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-26 09:54 EST | News | CollPlant receives substantial first order for its Vergenix™ FG in Ukraine | N/A | |
| 2020-10-08 21:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-15 06:11 EST | News | CollPlant Biotechnologies signs distribution pact for its gel product | N/A | |
| 2020-08-30 07:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-28 17:30 EST | News | CollPlant EPS beats by $0.53, misses on revenue | N/A | |
| 2020-08-14 12:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 20:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 12:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 21:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 01:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:50 EST | Financials | Company financials have been released. | Neutral | |
About CollPlant Biotechnologies Ltd (CLGN):
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
General
- Name CollPlant Biotechnologies Ltd
- Symbol CLGN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 38
- Last Split Factor2:3
- Last Split Date2016-11-21
- Fiscal Year EndDecember
- IPO Date2018-01-30
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.collplant.com
View More
Valuation
- Forward PE 10.06
- Price/Sales (Trailing 12 Mt.) 15.66
- Price/Book (Most Recent Quarter) 19.19
- Enterprise Value Revenue 21.63
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate $0.23
- Profit Margin -122%
- Operating Margin -91%
- Return on Assets -27%
- Return on Equity -268%
- Revenue 6.02 million
- Earnings Per Share -$0.82
- Revenue Per Share $0.91
- Gross Profit 439000
- Quarterly Earnings Growth 510.9%
View More
Highlights
- Market Capitalization 123.73 million
- EBITDA -3208455
- Analyst Target Price $23
- Book Value Per Share $1.05
View More
Share Statistics
- Shares Outstanding 9.29 million
- Shares Float 4.11 million
- % Held by Insiders 3481%
- % Held by Institutions 13.55%
- Shares Short 3188
- Shares Short Prior Month 2980
- Short Ratio 0.01
View More
Technicals
- Beta 0.63
- 52 Week High $24.26
- 52 Week Low $6.19
- 50 Day Moving Average 16.47
- 200 Day Moving Average 10.97
View More
Dividends
- Dividend Date 2016-11-21
- ExDividend Date N/A
- Dividend Yield 0%
View More
CollPlant Biotechnologies Ltd (CLGN) Dividend Calendar:
CLGN's last dividend payment was made to shareholders on November 21, 2016.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
CollPlant Biotechnologies Ltd (CLGN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-01 | $N/A | $0.11 | $1.90 | -94.21% |
| 2020-06-30 | 2020-08-28 | $N/A | -$0.28 | -$0.25 | -12.79% |
| 2020-03-31 | 2020-04-01 | $609000 | -$0.77 | -$0.13 | -490.91% |
| 2019-12-31 | 2019-12-31 | $439000 | -$0.25 | -$0.25 | 0% |
| 2019-09-30 | 2019-11-29 | $679000 | -$0.69 | -$0.26 | -164.4% |
| 2019-06-30 | 2019-09-26 | $606000 | -$0.33 | ||
| 2019-03-31 | 2019-04-01 | $594000 | $0.01 | $0.01 | -48.11% |
| 2018-12-31 | 2019-03-31 | $15.79 million | -$0.29 | ||
| 2018-09-30 | 2018-11-29 | $813000 | -$0.01 | ||
| 2018-06-30 | 2018-09-21 | $653000 | -$0.36 | ||
| 2018-03-31 | 2018-05-24 | $220880.12 | -$0.61 | ||
| 2017-12-31 | 2018-03-21 | $442926.72 | -$0.51 | ||
| 2017-09-30 | 2017-09-30 | $68000 | -$0.01 | ||
| 2017-06-30 | 2017-06-30 | $6000 | -$0.01 | ||
| 2017-03-31 | 2017-03-31 | $69000 | -$0.01 | ||
| 2016-12-31 | 2016-12-31 | -$0.02 | |||
| 2016-09-30 | 2016-09-30 | -$0.05 | |||
| 2016-06-30 | 2016-06-30 | -$0.02 | |||
| 2016-03-31 | 2016-03-31 | -$0.02 | |||
| 2015-12-31 | 2015-12-31 | -$0.01 | |||
| 2015-09-30 | 2015-09-30 | -$0.01 | |||
| 2015-06-30 | 2015-06-30 | -$0.01 |
CollPlant Biotechnologies Ltd (CLGN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
CollPlant Biotechnologies Ltd (CLGN) Chart:
CollPlant Biotechnologies Ltd (CLGN) News:
Below you will find a list of latest news for CollPlant Biotechnologies Ltd (CLGN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
CollPlant Biotechnologies Ltd (CLGN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-04-19 | 2.5 | 0 | CALL | 0 | 0 | 948.69 | TRUE | 0 | 0 |
| 2024-04-19 | 5 | 0.7 | CALL | 0 | 7 | 136.84 | TRUE | 0 | 0 |
| 2024-04-19 | 7.5 | 0.3 | CALL | 0 | 9 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 10 | 0.45 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 12.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 2.5 | 0.3 | PUT | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 5 | 0.55 | PUT | 0 | 21 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 7.5 | 1.65 | PUT | 0 | 1 | 664.74 | TRUE | 0 | 0 |
| 2024-04-19 | 10 | 4.4 | PUT | 0 | 1 | 383.42 | TRUE | 0 | 0 |
| 2024-04-19 | 12.5 | 0 | PUT | 0 | 0 | 855.87 | TRUE | 0 | 0 |
| 2024-05-17 | 2.5 | 0 | CALL | 0 | 0 | 157.85 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | CALL | 0 | 0 | 84.03 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 10 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 92.12 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 206 | TRUE | 0 | 0 |
| 2024-05-17 | 10 | 0 | PUT | 0 | 0 | 197.94 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 2.98 | CALL | 0 | 1 | 186.14 | TRUE | 0 | 0 |
| 2024-07-19 | 5 | 0 | CALL | 0 | 0 | 63.37 | TRUE | 0 | 0 |
| 2024-07-19 | 7.5 | 0 | CALL | 0 | 0 | 101.28 | FALSE | 0 | 0 |
| 2024-07-19 | 10 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 0.6 | PUT | 0 | 2 | 74.84 | FALSE | 0 | 0 |
| 2024-07-19 | 7.5 | 0 | PUT | 0 | 0 | 93.8 | TRUE | 0 | 0 |
| 2024-07-19 | 10 | 0 | PUT | 0 | 0 | 190.88 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 0 | CALL | 0 | 0 | 418.06 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 0 | CALL | 0 | 0 | 73.67 | TRUE | 0 | 0 |
| 2024-10-18 | 7.5 | 0.4 | CALL | 1 | 1 | 67.18 | FALSE | 0.4 | 0 |
| 2024-10-18 | 10 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 0 | PUT | 0 | 0 | 66.17 | FALSE | 0 | 0 |
| 2024-10-18 | 7.5 | 0 | PUT | 0 | 0 | 83.97 | TRUE | 0 | 0 |
| 2024-10-18 | 10 | 0 | PUT | 0 | 0 | 75.54 | TRUE | 0 | 0 |
Latest CLGN Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 5:20 PM EST | 100 | $8.17 |
| Jun 13, 2022 1:30 PM EST | 100 | $8.5 |
| Jun 13, 2022 7:17 PM EST | 100 | $8.03 |
| Jun 13, 2022 7:17 PM EST | 44 | $8.02 |
CollPlant Biotechnologies Ltd (CLGN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-05 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1631487/999999999520001359/9999999995-20-001359-index.htm |
| 2020-06-04 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1631487/000000000020004971/0000000000-20-004971-index.htm |
| 2019-09-16 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631487/000110465919050200/0001104659-19-050200-index.htm |
| 2019-09-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631487/000110465919050575/0001104659-19-050575-index.htm |
| 2019-09-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631487/000110465919050576/0001104659-19-050576-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1631487/000117891320000365/0001178913-20-000365-index.htm |
| 2019-06-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019010152/0001213900-19-010152-index.htm |
| 2019-06-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019011089/0001213900-19-011089-index.htm |
| 2019-06-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1631487/000121390019011109/0001213900-19-011109-index.htm |
| 2019-07-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019012530/0001213900-19-012530-index.htm |
| 2019-08-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019014555/0001213900-19-014555-index.htm |
| 2019-08-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019014966/0001213900-19-014966-index.htm |
| 2019-08-12 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1631487/000121390019015250/0001213900-19-015250-index.htm |
| 2019-08-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019016224/0001213900-19-016224-index.htm |
| 2019-08-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019016598/0001213900-19-016598-index.htm |
| 2019-08-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019017036/0001213900-19-017036-index.htm |
| 2019-09-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019017097/0001213900-19-017097-index.htm |
| 2019-09-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019017456/0001213900-19-017456-index.htm |
| 2019-09-10 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1631487/000121390019017636/0001213900-19-017636-index.htm |
| 2019-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019018141/0001213900-19-018141-index.htm |
| 2019-09-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019018950/0001213900-19-018950-index.htm |
| 2019-10-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019021662/0001213900-19-021662-index.htm |
| 2019-11-05 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1631487/000121390019022022/0001213900-19-022022-index.htm |
| 2019-11-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019024491/0001213900-19-024491-index.htm |
| 2019-11-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019025016/0001213900-19-025016-index.htm |
| 2019-12-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019026517/0001213900-19-026517-index.htm |
| 2019-12-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390019027307/0001213900-19-027307-index.htm |
| 2020-01-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020000209/0001213900-20-000209-index.htm |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020000851/0001213900-20-000851-index.htm |
| 2020-02-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020002466/0001213900-20-002466-index.htm |
| 2020-02-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020003025/0001213900-20-003025-index.htm |
| 2020-02-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020003745/0001213900-20-003745-index.htm |
| 2020-03-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020005629/0001213900-20-005629-index.htm |
| 2020-03-09 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1631487/000121390020005755/0001213900-20-005755-index.htm |
| 2020-04-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020008283/0001213900-20-008283-index.htm |
| 2020-04-01 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020008285/0001213900-20-008285-index.htm |
| 2020-04-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020008771/0001213900-20-008771-index.htm |
| 2020-05-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020012294/0001213900-20-012294-index.htm |
| 2020-05-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020013493/0001213900-20-013493-index.htm |
| 2020-05-27 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1631487/000121390020013527/0001213900-20-013527-index.htm |
| 2020-06-04 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1631487/000121390020014083/0001213900-20-014083-index.htm |
| 2020-06-05 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020014237/0001213900-20-014237-index.htm |
| 2020-08-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020024100/0001213900-20-024100-index.htm |
| 2020-08-28 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1631487/000121390020024251/0001213900-20-024251-index.htm |
| 2020-09-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020024801/0001213900-20-024801-index.htm |
| 2020-09-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020026346/0001213900-20-026346-index.htm |
| 2020-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020027440/0001213900-20-027440-index.htm |
| 2020-10-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020030964/0001213900-20-030964-index.htm |
| 2020-10-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1631487/000121390020033141/0001213900-20-033141-index.htm |
| 2020-06-05 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1631487/999999999520001359/9999999995-20-001359-index.htm |